Deltec Asset Management LLC lifted its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 86.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 361,804 shares of the company's stock after purchasing an additional 167,680 shares during the quarter. Deltec Asset Management LLC owned about 1.25% of Aerovate Therapeutics worth $908,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. GTS Securities LLC acquired a new stake in shares of Aerovate Therapeutics in the 4th quarter worth $27,000. Ieq Capital LLC purchased a new position in Aerovate Therapeutics during the fourth quarter worth about $38,000. Russell Investments Group Ltd. boosted its holdings in Aerovate Therapeutics by 110.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock valued at $40,000 after purchasing an additional 7,977 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Aerovate Therapeutics in the 4th quarter valued at approximately $52,000. Finally, Rhumbline Advisers increased its holdings in shares of Aerovate Therapeutics by 67.3% during the 1st quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after buying an additional 9,154 shares during the last quarter.
Aerovate Therapeutics Price Performance
AVTE traded up $0.48 during trading hours on Friday, reaching $9.89. The company's stock had a trading volume of 2,139,909 shares, compared to its average volume of 14,153. The business's 50-day moving average is $27.17 and its 200-day moving average is $67.12. The stock has a market cap of $286.66 million, a PE ratio of -3.31 and a beta of 0.95. Aerovate Therapeutics, Inc. has a fifty-two week low of $47.60 and a fifty-two week high of $105.00.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.50) by $7.35. Analysts expect that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.
Aerovate Therapeutics Dividend Announcement
The firm also recently declared a dividend, which was paid on Monday, April 28th. Shareholders of record on Friday, April 25th were paid a dividend of $84.00 per share. The ex-dividend date was Tuesday, April 29th.
Aerovate Therapeutics Profile
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
